NDT Advance Access published online on April 3, 2007
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfm066
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials
1Department of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai and 2Department of Nephrology, Hangzhou Traditional Chinese Medical Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province China
Correspondence and offprint requests to: Prof. Chen Nan, Department of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China. Email: chen-nan{at}medmail.com.cn
 |
Abstract |
|---|
Background. The outcomes of previous trials of mycophenolate mofetil (MMF) in treating severe lupus nephritis (LN) are not in exact agreement. This meta-analysis of randomized controlled trials (RCTs) assesses the benefits and harms of MMF in the induction and maintenance therapy of severe LN.
Methods. We searched Medline, EMBASE and the Cochrane Collaboration Database for RCTs that compared MMF with other immunorepressive regimens for treating lupus nephritis and extracted data for remissions, side effects and prognosis in induction therapy and prognosis and side effects in maintenance therapy, and we summarized the combined results of the data of the RCTs as relative risk (RR).
Results. We analysed five RCTs with 307 patients—four RCTS providing the data for comparing MMF with cyclophosphamide (CYC) for induction therapy and two RCTs providing the data for comparing MMF with azathioprine (AZA) for maintenance therapy of severe LN. Overall, compared with CYC, induction therapy with MMF reduced the risk of infection significantly (RR 0.65, P < 0.001). It also significantly increased the complete remission rate compared with intravenous CYC (RR 3.10, P = 0.006). Compared with intravenous CYC, induction therapy with MMF reduced the incidence of leucopenia significantly (RR 0.66, P = 0.04). The prognosis and other side effects were not significantly different between MMF and CYC induction therapies. There was no significant difference between the patients receiving MMF and those receiving AZA for maintenance therapy in prognosis or the risks of amenorrhoea and herpes zoster.
Conclusions. MMF has higher efficacy in inducing remission in severe LN than pulsed intravenous therapy with CYC. Induction therapy with MMF is also associated with fewer side effects than induction therapy with CYC. Compared with AZA, MMF also is an alternative for maintenance therapy of severe LN without significant difference in the prognosis or risks of amenorrhoea and herpes zoster.
Keywords: azathioprine; cyclophosphamide; immunosuppression; lupus nephritis; meta-analysis; mycophenolate mofetil
Received for publication: 20. 8.06
Accepted in revised form: 19. 1.07
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Pepper, M. Griffith, C. Kirwan, J. Levy, D. Taube, C. Pusey, L. Lightstone, and T. Cairns Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3717 - 3723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. M. Berden Azathioprine, the Cinderella in the treatment of lupus nephritis Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2611 - 2612. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mak, A. A. C. Cheak, J. Y. S. Tan, H. C. Su, R. C. M. Ho, and C. S. Lau Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression Rheumatology, August 1, 2009; 48(8): 944 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Appel, G. Contreras, M. A. Dooley, E. M. Ginzler, D. Isenberg, D. Jayne, L.-S. Li, E. Mysler, J. Sanchez-Guerrero, N. Solomons, et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1103 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Roland, C Barbet, G Paintaud, C Magdelaine-Beuzelin, E Diot, J. Halimi, Y Lebranchu, H Nivet, and M Buchler Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study Lupus, April 1, 2009; 18(5): 441 - 447. [Abstract] [PDF]
|
|
|
|
|
|
Z Wang, Z Tang, H. Zhang, W. Hu, Z. Liu, and L. Li Clinicopathological characteristics of familial SLE patients with lupus nephritis Lupus, March 1, 2009; 18(3): 243 - 248. [Abstract] [PDF]
|
|
|
|
|
|
F Falcini, S Capannini, G Martini, F La Torre, A Vitale, F Mangiantini, F Nacci, M. Cerinic, R Cimaz, and F Zulian Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study Lupus, February 1, 2009; 18(2): 139 - 143. [Abstract] [PDF]
|
|
|
|
 |
|
 T. L. RIVERA, H. M. BELMONT, S. MALANI, M. LATORRE, L. BENTON, J. WEISSTUCH, L. BARISONI, C.-E TSENG, P. M. IZMIRLY, J. P. BUYON, et al. Current Therapies for Lupus Nephritis in an Ethnically Heterogeneous Cohort J Rheumatol, February 1, 2009; 36(2): 298 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. M. de Winter and T. van Gelder Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3386 - 3388. [Full Text] [PDF]
|
|
|
|
|
|
J. Lv, H. Zhang, Z. Cui, T. Su, Y. Zhang, and H. Wang Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2868 - 2872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chrysochou, H. Randhawa, R. Reeve, S. Waldek, G. N. Wood, D. J. O'Donoghue, and P. A. Kalra Determinants of renal functional outcome in lupus nephritis: a single centre retrospective study QJM, April 1, 2008; 101(4): 313 - 316. [Abstract] [Full Text] [PDF]
|
|